Moderna vaccine in New York (Bloomberg)
The Immunity arising from moderna vaccine Against covid-19 At least one yearOn Monday, the US laboratory indicated that it plans to deliver up to 1,000 million doses in 2021.
The manufacturer, at the JP Morgan Healthcare conference, said it was confident the messenger RNA (mRNA) technology it used was suitable for deploying a vaccine based on the new variant of the coronavirus that has emerged in a handful of countries.
A study was published in December in New England Journal of Medicine He argued that the vaccine-generated antibodies persisted 90 days After inoculation, an expected “slight” decrease in the level of antibodies in the vaccinated participants, however To a degree it remained high and above normal immunity Detected in patients who had contracted the Covid-19 virus and recovered.
Now, the lab’s forecast is much more optimistic than that proven threshold.
The company’s vaccine, called mRNA-1273, mimics the surface of the coronavirus and teaches the immune system to recognize and neutralize it.
Anthony Fauci, director of the Infectious Diseases Institute, said this weeks ago He was “sure” that the immune memory generated by the vaccine would last for some time. “We don’t know if it will take a year or two, three or five years, and we don’t knowOnly time will tell.
Moderna said in December it would run tests to ensure the vaccine is effective against any strain.
The company said on Monday that it expects to deliver between 600 million and 1 billion doses of its vaccine in 2021 and forecast vaccine sales of $ 11.7 billion for this year, based on pre-purchase agreements signed with governments. . “The team is very satisfied with the proven track record that we have right now … We are on the right track to deliver at least 600 million doses,” said CEO Stefan Bansel.
(Information from Reuters and AFP)
AstraZeneca has requested the European Union to obtain a permit for a vaccine against COVID-19
$ 5 billion will be earmarked for vaccine logistics this year in 92 countries